Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes

scientific article published on 12 November 2018

Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1109828041
P356DOI10.1038/S41418-018-0228-Y
P698PubMed publication ID30420758

P50authorBenjamin T. KileQ46040375
Daniel H GrayQ48358835
Fernando Souza-Fonseca-GuimaraesQ56783216
Nicholas D HuntingtonQ59559817
Jai RautelaQ88169955
P2093author name stringDavid Huang
Andrew M Lew
Emma M Carrington
David S Ritchie
Mandy J Ludford-Menting
Joanne E Davis
Rachel Koldej
Rebecca B Delconte
Wilford Goh
Yuhao Jiao
P2860cites workEffective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantationQ46848879
A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.Q50967594
Antilymphocyte Globulin for Chronic Graft-versus-Host DiseaseQ59281229
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesQ59286691
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferationQ77658417
Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseQ87635679
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsQ27683708
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient miceQ28594052
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaQ33438494
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).Q34100754
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1.Q34184126
Acute Graft-versus-Host Disease: Novel Biological InsightsQ34497574
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaQ34504188
IL-15 availability conditions homeostasis of peripheral natural killer T cellsQ34807830
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trialQ34998580
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignanciesQ35083281
Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptorQ35546855
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanismQ36351357
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyQ36862931
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Q37272164
Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe-/- mice lacking macrophage Bcl-2.Q37317950
Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse modelQ37330859
Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host diseaseQ37388077
One million haemopoietic stem-cell transplants: a retrospective observational studyQ38384271
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.Q38650669
Graft-versus-host disease versus graft-versus-leukemiaQ38659485
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.Q38700150
GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.Q38727251
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer modelsQ38736457
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesQ38852431
Cell cycle progression dictates the requirement for BCL2 in natural killer cell survivalQ39037263
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.Q40843566
Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT EffectsQ40936847
A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in miceQ41627096
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer modelsQ41865091
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells.Q45301087
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo.Q45301393
Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysisQ45851521
P433issue8
P304page(s)1516-1530
P577publication date2018-11-12
P1433published inCell Death & DifferentiationQ2943974
P1476titleRecipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes
P478volume26

Reverse relations

Q92540859Impacts of exercise interventions on different diseases and organ functions in micecites workP2860

Search more.